Home » Biosimilar Monoclonal Antibodies Market
Biosimilar Monoclonal Antibodies Market
Published date: Oct 2021 •Formats:
Request Sample Schedule a Call

Global Biosimilar Monoclonal Antibodies Market By Type (Human Growth Hormones, Monoclonal Antibodies, Insulin, Peptides, Erythropoietin, And Others), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, And Others), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2019-2028

  • Published date: Oct 2021
  • Report ID: 12866
  • Number of Pages: 284
  • Format:
  • keyboard_arrow_up
    • 1. Biosimilar Monoclonal Antibodies Market Introduction
      • 1.1. Definition
      • 1.2. Taxonomy
      • 1.3. Research Scope
    • 2. Executive Summary
      • 2.1. Key Findings by Major Segments
      • 2.2. Top strategies by Major Players
    • 3. Global Biosimilar Monoclonal Antibodies Market Overview
      • 3.1. Biosimilar Monoclonal Antibodies Market Dynamics
        • 3.1.1. Drivers
        • 3.1.2. Opportunities
        • 3.1.3. Restraints
        • 3.1.4. Challenges
      • 3.2. PESTLE Analysis
      • 3.3. Opportunity Map Analysis
      • 3.4. PORTER'S Five Forces Analysis
      • 3.5. Market Competition Scenario Analysis
      • 3.6. Product Life Cycle Analysis
      • 3.7. Opportunity Orbits
      • 3.8. Manufacturer Intensity Map
    • 4. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
      • 4.1. Global Biosimilar Monoclonal Antibodies Market Analysis by Type: Introduction
      • 4.2. Market Size and Forecast by Region
      • 4.3. Rituximab
      • 4.4. Infliximab
      • 4.5. Abciximab
      • 4.6. Trastuzumab
      • 4.7. Adalimumab
      • 4.8. Bevacizumab
    • 5. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
      • 5.1. Global Biosimilar Monoclonal Antibodies Market Analysis by Application: Introduction
      • 5.2. Market Size and Forecast by Region
      • 5.3. Oncology
      • 5.4. Chronic and Autoimmune Diseases
      • 5.5. Growth Hormone Deficiency
      • 5.6. Infectious Diseases
      • 5.7. Others
    • 6. Global Biosimilar Monoclonal Antibodies Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
      • 6.1. North America
        • 6.1.1. North America Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
          • 6.1.1.1. US
          • 6.1.1.2. Canada
          • 6.1.1.3. Mexico
      • 6.2.1. Europe
        • 6.2.1. Europe Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
          • 6.2.1.1. Germany
          • 6.2.1.2. France
          • 6.2.1.3. UK
          • 6.2.1.4. Russia
          • 6.2.1.5. Italy
          • 6.2.1.6. Spain
          • 6.2.1.7. Rest of Europe
      • 6.3. Asia-Pacific
        • 6.3.1. Asia-Pacific Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
          • 6.3.1.1. China
          • 6.3.1.2. Japan
          • 6.3.1.3. Korea
          • 6.3.1.4. India
          • 6.3.1.5. Rest of Asia
      • 6.4. Latin America
        • 6.4.1. Latin America Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
          • 6.4.1.1. Brazil
          • 6.4.1.2. Argentina
          • 6.4.1.3. Rest of Latin America
      • 6.5. Middle East and Africa
        • 6.5.1. Middle East and Africa Biosimilar Monoclonal Antibodies Market: Regional Trend Analysis
          • 6.5.1.1. GCC
          • 6.5.1.2. South Africa
          • 6.5.1.3. Israel
          • 6.5.1.4. Rest of MEA
    • 7. Global Biosimilar Monoclonal Antibodies Market Competitive Landscape, Market Share Analysis, and Company Profiles
      • 7.1. Market Share Analysis
      • 7.2. Company Profiles
      • 7.3. Pfizer, Inc.
        • 7.3.1. Company Overview
        • 7.3.2. Financial Highlights
        • 7.3.3. Product Portfolio
        • 7.3.4. SWOT Analysis
        • 7.3.5. Key Strategies and Developments
      • 7.4. Novartis AG
        • 7.4.1. Company Overview
        • 7.4.2. Financial Highlights
        • 7.4.3. Product Portfolio
        • 7.4.4. SWOT Analysis
        • 7.4.5. Key Strategies and Developments
      • 7.5. Reliance Life Sciences
        • 7.5.1. Company Overview
        • 7.5.2. Financial Highlights
        • 7.5.3. Product Portfolio
        • 7.5.4. SWOT Analysis
        • 7.5.5. Key Strategies and Developments
      • 7.6. Allergan plc
        • 7.6.1. Company Overview
        • 7.6.2. Financial Highlights
        • 7.6.3. Product Portfolio
        • 7.6.4. SWOT Analysis
        • 7.6.5. Key Strategies and Developments
      • 7.7. Coherus BioSciences, Inc.
        • 7.7.1. Company Overview
        • 7.7.2. Financial Highlights
        • 7.7.3. Product Portfolio
        • 7.7.4. SWOT Analysis
        • 7.7.5. Key Strategies and Developments
      • 7.8. Biocon
        • 7.8.1. Company Overview
        • 7.8.2. Financial Highlights
        • 7.8.3. Product Portfolio
        • 7.8.4. SWOT Analysis
        • 7.8.5. Key Strategies and Developments
      • 7.9. Dr. Reddy's Laboratories Ltd.
        • 7.9.1. Company Overview
        • 7.9.2. Financial Highlights
        • 7.9.3. Product Portfolio
        • 7.9.4. SWOT Analysis
        • 7.9.5. Key Strategies and Developments
      • 7.10. Boehringer Ingelheim GmbH
        • 7.10.1. Company Overview
        • 7.10.2. Financial Highlights
        • 7.10.3. Product Portfolio
        • 7.10.4. SWOT Analysis
        • 7.10.5. Key Strategies and Developments
      • 7.11. BioXpress Therapeutics SA
        • 7.11.1. Company Overview
        • 7.11.2. Financial Highlights
        • 7.11.3. Product Portfolio
        • 7.11.4. SWOT Analysis
        • 7.11.5. Key Strategies and Developments
      • 7.12. Intas Pharmaceuticals Limited
        • 7.12.1. Company Overview
        • 7.12.2. Financial Highlights
        • 7.12.3. Product Portfolio
        • 7.12.4. SWOT Analysis
        • 7.12.5. Key Strategies and Developments
      • 7.13. BIOCAD
        • 7.13.1. Company Overview
        • 7.13.2. Financial Highlights
        • 7.13.3. Product Portfolio
        • 7.13.4. SWOT Analysis
        • 7.13.5. Key Strategies and Developments
      • 7.14. Genor BioPharma Co. Ltd
        • 7.14.1. Company Overview
        • 7.14.2. Financial Highlights
        • 7.14.3. Product Portfolio
        • 7.14.4. SWOT Analysis
        • 7.14.5. Key Strategies and Developments
      • 7.15. Celltrion, Inc.
        • 7.15.1. Company Overview
        • 7.15.2. Financial Highlights
        • 7.15.3. Product Portfolio
        • 7.15.4. SWOT Analysis
        • 7.15.5. Key Strategies and Developments
    • 8. Assumptions and Acronyms
    • 9. Research Methodology
    • 10. Contact
    • Pfizer, Inc.
    • Novartis AG Company Profile
    • Reliance Life Sciences
    • Allergan plc
    • Coherus BioSciences, Inc.
    • Biocon
    • Dr. Reddy's Laboratories Ltd.
    • Boehringer Ingelheim GmbH
    • BioXpress Therapeutics SA
    • Intas Pharmaceuticals Limited
    • BIOCAD
    • Genor BioPharma Co. Ltd
    • Celltrion, Inc.
  • settingsSettings

Related Reports

Our Clients

  • Our Clients
Inquiry Before Buying

Biosimilar Monoclonal Antibodies Market
  • 12866
  • Oct 2021
    • ★★★★★
      ★★★★★
    • (81)
  • US $5,999
    US $2,999
  • US $7,999
    US $3,499
  • US $12,999
    US $4,499
Buy Now
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$5,999
$2,999
USD / per unit
save 50%
 Multi User
$7,999
$3,499
USD / per unit
save 55%
 Corporate User
$12,999
$4,499
USD / per unit
save 65%
e-Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 2,999)Buy Now ($ 3,499)Buy Now ($ 4,499)
Find Help
Legal
Explore